

J R Chalmers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3487846/publications.pdf>

Version: 2024-02-01

79
papers

3,519
citations

201674

27
h-index

144013

57
g-index

80
all docs

80
docs citations

80
times ranked

3124
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of childhood atopic dermatitis on life decisions for caregivers and families. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	5
2	Supporting families managing childhood eczema: developing and optimising eczema care online using qualitative research. British Journal of General Practice, 2022, 72, e378-e389.	1.4	7
3	Strategies for using topical corticosteroids in children and adults with eczema. The Cochrane Library, 2022, 2022, CD013356.	2.8	18
4	The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 149, 1899-1911.	2.9	51
5	Prescribing and using vitiligo treatments “ lessons from a nested Process Evaluation within the <sc>HLight</sc> Vitiligo Randomised Controlled Trial. Clinical and Experimental Dermatology, 2022, , .	1.3	0
6	Eczema Care Online: development and qualitative optimisation of an online behavioural intervention to support self-management in young people with eczema. BMJ Open, 2022, 12, e056867.	1.9	6
7	Randomized controlled trial of topical corticosteroid and homeâ€based narrowband ultraviolet B for active and limited vitiligo: results of the HLight Vitiligo Trial*. British Journal of Dermatology, 2021, 184, 828-839.	1.5	25
8	The effect of water hardness on atopic eczema, skin barrier function: A systematic review, metaâ€analysis. Clinical and Experimental Allergy, 2021, 51, 430-451.	2.9	15
9	Association of frequent moisturizer use in early infancy with the development of food allergy. Journal of Allergy and Clinical Immunology, 2021, 147, 967-976.e1.	2.9	50
10	Scoping the international impact from four independent national dermatology trials. Clinical and Experimental Dermatology, 2021, 46, 657-662.	1.3	2
11	An economic evaluation of the randomized controlled trial of topical corticosteroid and homeâ€based narrowband ultraviolet B for active and limited vitiligo (the HLight Vitiligo Trial)*. British Journal of Dermatology, 2021, 184, 840-848.	1.5	6
12	Testâ€guided dietary management of eczema in children: A randomized controlled feasibility trial (TEST). Clinical and Experimental Allergy, 2021, 51, 452-462.	2.9	9
13	Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England. BMC Medical Research Methodology, 2021, 21, 22.	3.1	0
14	Skin care interventions in infants for preventing eczema and food allergy. The Cochrane Library, 2021, 2021, CD013534.	2.8	37
15	Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care) Tj ETQq1 1 0.784314 rgBT /Overlo	1.9	12
16	Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data metaâ€analysis. Clinical and Experimental Allergy, 2021, 51, 402-418.	2.9	38
17	Recommended core outcome instruments for healthâ€related quality of life, longâ€term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. British Journal of Dermatology, 2021, 185, 139-146.	1.5	52
18	Do patient characteristics matter when calculating sample size for eczema clinical trials?. Skin Health and Disease, 2021, 1, e42.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Measurement properties of patient-reported outcome measures for eczema control: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1987-1993.	2.4	6
20	Safety of topical corticosteroids in atopic eczema: an umbrella review. <i>BMJ Open</i> , 2021, 11, e046476.	1.9	32
21	Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study. <i>British Journal of General Practice</i> , 2021, 71, e904-e911.	1.4	1
22	Clinical examination for hyperlinear palms to determine filaggrin genotype: A diagnostic test accuracy study. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1421-1428.	2.9	5
23	Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (<scp>RECAP</scp>). <i>British Journal of Dermatology</i> , 2020, 183, 524-536.	1.5	52
24	An algorithm for diagnosing IgE-mediated food allergy in study participants who do not undergo food challenge. <i>Clinical and Experimental Allergy</i> , 2020, 50, 334-342.	2.9	14
25	Two-by-two factorial randomised study within a trial (SWAT) to evaluate strategies for follow-up in a randomised prevention trial. <i>Trials</i> , 2020, 21, 529.	1.6	8
26	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2020, 185, 139.	1.5	7
27	Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments. <i>British Journal of Dermatology</i> , 2020, 183, 566-568.	1.5	13
28	Skincare interventions in infants for preventing eczema and food allergy. <i>The Cochrane Library</i> , 2020, , .	2.8	7
29	Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. <i>Lancet, The</i> , 2020, 395, 962-972.	13.7	178
30	Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1181-1186.	1.2	29
31	Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-128.	2.8	18
32	Defining and measuring "eczema control": an international qualitative study to explore the views of those living with and treating atopic eczema. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1124-1132.	2.4	16
33	Navigating the landscape of core outcome set development in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 297-305.	1.2	46
34	TEST (Trial of Eczema allergy Screening Tests): protocol for feasibility randomised controlled trial of allergy tests in children with eczema, including economic scoping and nested qualitative study. <i>BMJ Open</i> , 2019, 9, e028428.	1.9	6
35	Patients' understanding of cellulitis and their information needs: a mixed-methods study in primary and secondary care. <i>British Journal of General Practice</i> , 2019, 69, e279-e286.	1.4	5
36	The Burden of Childhood Atopic Dermatitis in the Primary Care Setting: A Report from the Meta-LARC Consortium. <i>Journal of the American Board of Family Medicine</i> , 2019, 32, 191-200.	1.5	18

#	ARTICLE	IF	CITATIONS
37	Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. <i>BMJ Open</i> , 2019, 9, e027168.	1.9	8
38	Patients' understanding of cellulitis and views about how best to prevent recurrent episodes: mixed methods study in primary and secondary care. <i>British Journal of Dermatology</i> , 2019, 180, 810-820.	1.5	12
39	Spleen to liver stiffness ratio significantly differs between ALD and HCV and predicts disease-specific complications. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
40	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. <i>British Journal of Dermatology</i> , 2018, 178, e279-e285.	1.5	29
41	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2018, 178, e332-e341.	1.5	96
42	How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods. <i>British Journal of Dermatology</i> , 2018, 178, 1135-1142.	1.5	26
43	Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. <i>British Journal of Dermatology</i> , 2018, 178, 415-423.	1.5	13
44	Home interventions and light therapy for the treatment of vitiligo (HI-Light Vitiligo Trial): study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2018, 8, e018649.	1.9	8
45	Management of cellulitis: current practice and research questions. <i>British Journal of General Practice</i> , 2018, 68, 595-596.	1.4	12
46	Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. <i>British Journal of Dermatology</i> , 2018, 179, 540-541.	1.5	25
47	Towards a better understanding of outcome measurement instruments for atopic eczema. <i>British Journal of Dermatology</i> , 2018, 179, 246-247.	1.5	0
48	Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 146-163.	5.7	71
49	Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. <i>British Journal of Dermatology</i> , 2017, 176, 979-984.	1.5	141
50	Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. <i>Lancet, The</i> , 2017, 389, 1630-1638.	13.7	167
51	Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership. <i>British Journal of Dermatology</i> , 2017, 177, 541-543.	1.5	27
52	The BLISTER study: possible overestimation of tetracycline efficacy – Authors' reply. <i>Lancet, The</i> , 2017, 390, 735-736.	13.7	1
53	“When it goes back to my normal I suppose”: a qualitative study using online focus groups to explore perceptions of “control” among people with eczema and parents of children with eczema in the UK. <i>BMJ Open</i> , 2017, 7, e017731.	1.9	30
54	Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 343.	1.6	56

#	ARTICLE	IF	CITATIONS
55	What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey. <i>Acta Dermato-Venereologica</i> , 2017, 97, 86-90.	1.3	45
56	A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200â€‰mg/day) with that of oral prednisolone (0.5â€‰mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. <i>Health Technology Assessment</i> , 2017, 21, 1-90.	2.8	17
57	Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review. <i>British Journal of Dermatology</i> , 2016, 175, 678-686.	1.5	34
58	Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 358-370.	5.7	56
59	Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN). <i>British Journal of Dermatology</i> , 2016, 174, 287-295.	1.5	41
60	A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. <i>British Journal of Dermatology</i> , 2016, 175, 1011-1019.	1.5	39
61	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2016, 175, 69-79.	1.5	115
62	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1038-1044.	1.2	35
63	A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease. <i>Programme Grants for Applied Research</i> , 2016, 4, 1-488.	1.0	5
64	Reaching clinically relevant outcome measures for new pharmacotherapy and immunotherapy of atopic eczema. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 227-233.	2.3	10
65	Clearing up misunderstandings around core outcomes for atopic dermatitis. <i>British Journal of Dermatology</i> , 2015, 173, 623-624.	1.5	3
66	A randomized controlled trial to compare the safety and effectiveness of doxycycline (200Âmg daily) with oral prednisolone (0.5Âmg/kg daily) for initial treatment of bullous pemphigoid: a protocol for		

#	ARTICLE	IF	CITATIONS
73	Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology, 2014, 134, 818-823.	2.9	594
74	The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Journal of Allergy and Clinical Immunology, 2014, 134, 800-807.	2.9	257
75	Penicillin to Prevent Recurrent Leg Cellulitis. New England Journal of Medicine, 2013, 368, 1695-1703.	27.0	149
76	Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1111-1117.	5.7	169
77	Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the U.K. Dermatology Clinical Trials Network's PATCH II trial. British Journal of Dermatology, 2012, 166, 169-178.	1.5	65
78	To freeze or not to freeze: a cost-effectiveness analysis of wart treatment. British Journal of Dermatology, 2007, 156, 687-692.	1.5	19
79	Different strategies for using topical corticosteroids in people with eczema. The Cochrane Library, 0, , .	2.8	6